Appendix 4E and Full Year Statutory Accounts
Released
Released
Announcement PDF
23 August 2024
Manager, Company Announcements
ASX Limited
Level 4
20 Bridge Street
SYDNEY NSW 2000
Via E-Lodgement
Dear Sir/Madam
Mayne Pharma Group Limited
Final Report and accompanying announcement
Please find attached the following documents relating to the results for the year ended 30 June
2024.
•
•
Appendix 4E
Annual Financial Statements
This announcement comprises the information required by ASX Listing Rule 4.3A.
Yours faithfully,
Mayne Pharma Group Limited
Laura Loftus
Company Secretary
RESULTS FOR ANNOUNCEMENT TO THE MARKET
APPENDIX 4E – PRELIMINARY FINAL REPORT
%
30 JUNE
30 JUNE
2024
2023
$’000
$’000
388,399
183,586
Profit / (loss) from continuing operations before income tax expense
(190,087)
(269,698)
Profit / (loss) from continuing operations after income tax expense
(168,619)
(317,443)
Profit / (loss) from discontinued operations after income tax expense
(5,614)
434,600
(174,233)
117,157
(174,233)
117,249
-
(92)
(174,233)
117,157
902
15,122
(173,331)
132,279
(173,331)
132,959
-
(680)
(173,331)
132,279
(1.45)
$0.21
2024
2023
$
$
Basic earnings per share
(2.19)
1.42
Diluted earnings per share
(2.19)
1.41
Nil
Nil
CHANGE
Revenue from ordinary activities
112%
Profit / (loss) after income tax
Attributable to:
Equity holders of the parent
Non-controlling interests
Other comprehensive profit/(loss) after income tax expense
Total comprehensive profit/(loss) for the period
Attributable to:
Equity holders of the parent
Non-controlling interests
Net tangible assets per ordinary share (1) (2)
Final dividend in respect of the financial year ended 30 June per share
Refer to the Review of Operations and Likely Developments and the accompanying ASX announcement dated 23 August 2024 for a brief
commentary on the results.
During the reporting period, Mayne Pharma incorporated a new entity Mayne Pharma Distribution Services LLC.
1.
2.
Includes right-of-use lease assets.
Impacted by the 20:1 share consolidation in the prior period.
Financial Report 2024
MAYNE PHARMA GROUP LIMITED
ABN 76 115 832 963
FOR THE YEAR ENDED 30 JUNE 2024
(PRIOR CORRESPONDING PERIOD: YEAR ENDED 30 JUNE 2023)
CONTENTS
DIRECTORS’ REPORT
2
REMUNERATION REPORT (AUDITED)
15
AUDITOR’S INDEPENDENCE DECLARATION
26
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
28
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
29
CONSOLIDATED STATEMENT OF CASH FLOWS
30
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
31
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
32
CONSOLIDATED ENTITY DISCLOSURE STATEMENT
70
DIRECTORS’ DECLARATION
71
INDEPENDENT AUDITOR’S REPORT
72
GLOSSARY
77
DIRECTORS’ REPORT
The Directors of Mayne Pharma Group Limited (‘the Company’) present their report together with the financial report of the Company and its
controlled entities (collectively the ‘Group’ or ‘Consolidated Entity’ or ‘Mayne Pharma’) for the year ended 30 June 2024 and the Auditor’s Report
thereon. The information set out below is to be read in conjunction with the Remuneration Report set out on pages 15 to 25, which forms part of this
Directors’ Report.
DIRECTORS
The Directors of the Company during the financial year and up to the date of this report are set out below. Directors were in office for this entire
period unless otherwise noted.
Mr Frank Condella, Chair
Mr Shawn Patrick O’Brien, Managing Director and CEO
Mr Patrick Blake
Ms Ann Custin
Mrs Anne Lockwood (appointed 30 November 2023)
Dr Kathryn MacFarlane
Dr Carolyn Myers (resigned 31 July 2023)
Mr David Petrie
Prof Bruce Robinson, AC
The Directors’ qualifications, other listed company directorships, experience and special responsibilities are detailed on pages 10 and 11 of this report.
The qualifications and experience of the Company Secretary are detailed on page 11 of this report.
DIRECTORS’ MEETINGS
The number of Directors’ meetings (including meetings of committees of Directors) and number of meetings attended by each of the Directors of the
Company during the 2024 financial year are:
BOARD
1.
2.
3.
4.
5.
AUDIT & RISK COMMITTEE
NOMINATION
COMMITTEE
REMUNERATION & PEOPLE
COMMITTEE
SCIENCE, TECHNOLOGY &
MEDICAL COMMITTEE
HELD1
ATTENDED2
HELD1
ATTENDED2
HELD1
ATTENDED2
HELD1
ATTENDED2
HELD1
ATTENDED2
Mr F Condella3
17
17
-
-
2
2
7
7
-
1
Mr S O’Brien3,4, 5
17
17
-
7
-
-
-
7
-
2
Mr P Blake
17
17
7
7
-
-
7
7
-
-
Ms A Custin5
17
17
7
7
-
-
-
2
-
-
Mrs A Lockwood4, 5
11
10
-
1
-
-
-
1
-
-
Dr K MacFarlane5
17
17
-
-
2
2
-
1
3
3
-
Dr C Myers
2
1
-
-
-
-
-
-
-
Mr D Petrie
17
17
7
7
-
-
7
7
-
-
Prof B Robinson 5
17
16
-
-
2
2
-
1
3
3
This column shows the number of meetings held during the period the Director was a member of the Board or Committee.
This column shows the number of meetings attended.
Mr O’Brien and Mr Condella are not members of the Science, Technology & Medical Committee however they attend meetings at the Chair’s invitation.
Mr O’Brien and Mrs Lockwood are not members of the Audit and Risk Committee however they attend meetings at the Chair’s invitation.
Mr O’Brien, Ms Custin, Mrs Lockwood, Dr MacFarlane and Professor Robinson are not members of the Remuneration and People Committee however they attend
meetings at the Chair’s invitation.
SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS
On 4 September 2023, Mayne Pharma announced the acquisition of the global rights to RHOFADE® from Novan Inc. The total cost of the acquisition
was $12.9m.
The Women’s Health segment has shown considerable growth with the full year impact of the expansion of the portfolio as well as the improved
performance of NEXTSTELLIS®. The performance of the Dermatology segment has also shown considerable growth with a material improvement to
the performance and the return to a profitable direct contribution. Direct contribution is gross margin less direct operating expenses (opex) and does
not include an allocation of corporate overheads.
Work has commenced on the Salisbury modernisation project for which Mayne Pharma has received a Federal Government Modern Manufacturing
Initiative (MMI) Grant. New equipment to be installed include a high speed encapsulator and a high-speed blister packing line with serialisation
capabilities.
During the prior comparative period (pcp) the Group announced the following transactions:
•
On 4 October 2022, Mayne Pharma completed the sale of the Metrics Contract Services (MCS) business to Catalent Pharma Solutions, Inc.
Following completion and after allowing for reinvestment needs, the Company used the net proceeds to repay the syndicated debt facility and
to pay a dividend to shareholders.
•
The Group completed an exclusive licence agreement effective 31 December 2022 to license products from TherapeuticsMD, Inc. (TXMD).
These assets have been added to the Women’s Health portfolio and CGU alongside NEXTSTELLIS®. In conjunction with the licence agreement
the Group issued US$27.95m of convertible notes.
•
The Group completed the sale of the Retail Generics business to Dr. Reddy’s Laboratories on 7 April 2023.
The Company also completed a 20:1 share consolidation in January 2023.
PRINCIPAL ACTIVITIES
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2024
2
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising branded women’s health and dermatology
pharmaceuticals.
Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been
successfully commercialised in numerous products that continue to be marketed around the world.
Mayne Pharma has a product development and manufacturing facility based in Salisbury, Australia with expertise in the formulation of complex oral
and topical dose forms including modified-release products and poorly soluble compounds.
REVIEW OF OPERATIONS AND LIKELY DEVELOPMENTS
Summary of financial performance
Set out below is a summary of the financial performance attributable to Mayne Pharma shareholders for the 2024 financial year (FY24) compared to
the prior corresponding period (pcp). The prior period includes Mayne Pharma’s share of Inhibitor Therapeutics Inc (INTI) for period during which
Mayne Pharma held control (i.e. up to 14 December 2022).
This summary includes non-IFRS financial information that is stated excluding certain non-operating income and expense items. The results are set
out this way as the Directors consider them to be a meaningful comparison from period to period that are useful for the users of this financial report
as they provide additional and relevant information that reflect the underlying performance of the business. Key measures of earnings considered by
management in operating the business and assessing performance are earnings before interest, tax, depreciation, amortisation and impairment
(‘EBITDA’) and Adjusted EBITDA.
2024
$M
2023
$M
CHANGE ON PCP
$M
Reported Revenue continuing operations
388.4
183.6
204.8
Reported Gross profit continuing operations
218.8
83.5
135.3
Reported Gross profit %
56.3%
45.5%
Adjusted EBITDA
22.9
(95.3)
118.2
Adjustments1
(115.4)
(6.7)
(108.7)
Reported EBITDA continuing operations
(92.5)
(102.0)
9.5
-
(69.2)
69.2
SALES AND PROFIT
Impairments
Depreciation / Amortisation
(68.5)
(65.4)
(3.1)
Reported Profit / (Loss) Before Interest and Tax continuing operations
(161.0)
(236.5)
75.5
Net interest
2.4
(3.7)
6.1
Foreign exchanges gains/(losses) financing activities
(1.1)
(11.0)
9.9
Earn-out & deferred consideration liabilities discount unwind
(30.3)
(18.4)
(11.9)
Reported Profit / (Loss) Before Tax continuing operations
(190.1)
(269.7)
79.6
21.5
(47.7)
69.2
(168.6)
(317.4)
148.8
Income tax credit / (expense)
Reported Net Profit / (Loss) After Tax attributable to Mayne Pharma shareholders
continuing operations
1.
Current year adjustments are included in the table below.
The reconciliation of reported results (from continuing operations) and adjusted results for the current year is as follows:
SALES AND PROFIT
REPORTED
ATTRIBUTABLE TO
MEMBERS JUNE
2024
$M
EARN-OUT
REASSESSMENTS1
$M
RESTRUCTURING2
$M
CLASS ACTION
SETTLEMENT3
$M
DERIVATIVE FAIR
VALUE
ADJUSTMENT4
$M
LITIGATION5
$M
ADJUSTED JUNE
2024
$M
Revenue
388.4
Gross profit
218.8
218.8
Gross profit %
56.3%
56.3%
EBITDA
(92.5)
Depreciation /
Amortisation
(68.5)
Asset impairments
PBIT
82.7
0.9
33.2
(2.8)
1.3
(161.0)
(29.0)
PBT
(190.1)
22.9
(68.5)
-
Net finance costs
1.
2.
3.
4.
5.
388.4
82.7
0.9
33.2
(2.8)
1.3
82.7
0.9
33.2
(2.8)
1.3
(45.6)
(29.0)
(74.7)
Non-cash debit arising from the net increase in earn-out and deferred consideration liabilities with the majority related to TXMD liability partially offset by a decrease for NEXTSTELLIS®.
Restructuring costs related to organisational transformation to simplify the operating model.
Class Action Settlement as per ASX announcement.
Fair value adjustment relating to the convertible notes derivative.
Drug pricing and health care investigations, US Department of Justice and related litigation costs.
Review of operations
In contrast to the above tables which are based on financial performance attributable to Mayne Pharma shareholders, the following information is
provided on a total group basis and hence includes 100% of the revenues and expenses incurred by Inhibitor Therapeutics Inc (INTI) where applicable.
Mayne Pharma held control 53.5% of INTI and consolidated 100% of INTI during the prior comparative period (pcp) during which Mayne Pharma held
control (ie up to 14 December 2022), in accordance with accounting standards, into the financial statements following this Directors’ Report.
On 4 September 2023, Mayne Pharma announced the acquisition of the global rights to RHOFADE® from Novan Inc for $12.9m.
The Group recorded revenue for continuing operations of $388.4m, up 112% on the prior comparative period (pcp) and gross profit for continuing
operations was $218.8m, up 162% on pcp.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2024
3
Gross profit margin for continuing operations as a percentage of revenue was 56.3% (2023: 45.5%) which reflects the growth of the Women’s Health
business (higher relative profitability business) and improvement in the dermatology business primarily RHOFADE®.
The reported loss before tax from continuing operations was $190.1m and the net loss after tax was $168.8m which includes $33.2m for the Class
Action settlement.
The impact of exchange rate movements on the Company’s balance sheet is recognised in the Foreign Currency Translation Reserve (FCTR) which
increased by $0.9m during the year.
Expenses
Net research, development medical and regulatory affairs expense (total costs less amounts qualifying for capitalisation) were $20.2m, an increase in
the expense of $4.5m (29%) on the pcp due to an investment in Medical Science Liaisons to raise product scientific awareness and an increase in
required studies on products licensed from TXMD which was offset by savings from changes in pharmacovigilance provider and agreements.
Total R&D, medical and regulatory affairs costs incurred
Development costs capitalised
R&D, medical and regulatory affairs expensed (includes
discontinued operations)
JUNE
2024
$M
JUNE
2023
$M
20.2
16.1
-
0.4
20.2
15.7
Marketing and distribution expenses increased by $4.8m (4%) to $130.7m. The majority of marketing and distribution costs relate to the US businesses
and hence are subject to currency rate translation – the currency translation impact was to increase the FY24 expense by $3.3m (compared to FY23
translation rate). In USD terms there was little change to the expense although distribution costs did increase in USD terms due to the increased
volumes.
Finance costs of $36.1m (2023: $39.9m) include the unwinding of discounts associated with earn-out liabilities and deferred liabilities which increased
to $30.3m from $18.4m in the pcp. The earnouts discount unwind includes NEXTSTELLIS® $12.1m (2023: $10.1m) and TXMD $16.3m (2023: $6.9m)
Included in finance costs are foreign exchange losses relating to financing activities of $1.1m (2023: $11.0m loss).
There were no impairments in the current period (2023: $69.2m).
Administration and other expenses increased by $5.4m (4%) to $147.9m. This category includes non-cash and other non-operating items such as:
•
•
•
•
•
•
•
•
Amortisation of intangible assets which was $59.7m (2023: $56.6m);
Class Action Settlement (net of insurance recovery) $33.2m (2023: nil);
Share based payments expense of $4.1m (2023: $6.8m which included restructuring and exiting the MCS business);
Drug pricing investigations and related litigation costs of $1.3m (2023: $5.1m);
A specific doubtful debt in 2023 of $7.8m;
Fair value movement on derivative of $2.8m credit (2023: $2.7m expense);
Loss on disposal of INTI in 2023 of $3.1m; and
Restructuring expenses of $0.9m (2023: $9.1m).
Excluding these items, administration and other expenses were $51.4m compared to $51.3m in 2023.
Tax
Tax benefit of $21.5m for continuing operations and tax benefit of $1.6m for discontinued operations comprised:
•
•
•
Current period income tax expense for the year to 30 June 2024 of ($1.8m);
A decrease in current year tax benefit in respect of prior years of $2.0m; and
Deferred income tax benefit of $22.8m.
Financial position
Set out below is a summary of the financial position as at 30 June 2024 compared to the position as at 30 June 2023.
BALANCE SHEET EXTRACT
2024
$M
2023
$M
CHANGE ON PCP
$M
CHANGE ON PCP
%
Cash
110.1
92.6
17.5
19%
Marketable securities
39.2
127.5
(88.3)
(69%)
Receivables
193.2
194.9
(1.7)
(1%)
Inventory
74.6
82.7
(8.1)
(10%)
Income tax receivable
14.5
14.6
(0.1)
(1%)
PP&E
46.7
43.7
3.0
7%
Intangible assets including goodwill
568.6
617.3
(48.7)
(8%)
Other assets
96.3
74.1
22.2
30%
Total assets
1,143.2
1,247.4
(104.2)
(8%)
Interest-bearing debt (including lease liabilities)
38.8
47.5
(8.7)
(18%)
Trade and other payables
244.5
246.5
(2.0)
(1%)
Other financial liabilities
381.8
296.2
85.6
29%
Other liabilities
23.9
22.8
1.1
5%
Total liabilities
689.0
613.0
76.0
12%
Equity
454.2
634.4
(180.2)
(28%)
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2024
4
The material changes to the operating assets and liabilities of the business were as follows:
Cash
Cash increased by $17.5m compared to 30 June 2023. In addition to cash, the Company also holds marketable securities of $39.2m which decreased
compared to 30 June 2023 by $88.3m.
Inventory, receivables and trade payables
Receivables at balance date include the insurance receivable relating to the Class Action ($4.7m) and a receivable from TXMD related to product
returns ($9.3m). Inventory decreased $8.1m (10%) as a result of wind up of discontinued products (RGx - $2.6m) and general inventory efficiency
improvements. Trade and other payables include $38m accrual for the Class Action settlement and a payable to third parties related to product
returns for sales prior to the license transaction with TXMD.
Intangible assets
Intangible assets decreased by $48.7m compared to the balance at 30 June 2023. The movement comprised of:
•
•
•
An increase of $12.9m for the RHOFADE® acquisition;
A decrease of $59.7m for amortisation; and
A decrease of $1.9m due to foreign currency translation as the AUD / USD exchange rate increased from 0.664 at 30 June 2023 to 0.6647 at 30
June 2024.
Property, plant & equipment
Property, plant and equipment increased by $3.0m compared to the balance at 30 June 2023. The movement comprised of:
•
•
An increase of $7.9m for additions net of disposals; and
A decrease of $5.0m for depreciation.
Interest bearing liabilities
Interest bearing liabilities (excluding lease liabilities) decreased to $31.6m from $39.3m at 30 June 2023. Convertible notes were issued in December
2022 to support the acquisition of the TXMD licensed assets. The convertible notes are repayable as a fixed AUD amount at maturity (if not converted).
The receivables financing facility was repaid during the period.
Other financial liabilities
The major items included in other financial liabilities as at 30 June 2024 were the earn-out liabilities and deferred consideration for the NEXTSTELLIS®
distribution rights and the TXMD earn-out and deferred consideration liabilities.
Other financial liabilities increased by $85.6m from 30 June 2023 due to:
•
•
•
•
•
An increase of $30.3m due to the unwinding of the discount for the various earn-out liabilities and deferred consideration liabilities including
$12.1m relating to the NEXTSTELLIS® deferred consideration liability and $16.3m relating to the TXMD earn-out liabilities;
An increase of $82.7m due to re-assessments which included the TXMD liabilities which were reassessed upwards by $88.6m due to increased
revenue forecasts for the products and the NEXTSTELLIS® liability which was reassessed downwards by $7.5m;
A decrease of $21.8m due to payments made;
A decrease of $2.8m due to the change in the fair value of the convertible notes related derivative; and
A decrease relating to foreign currency translation of $2.7m.
Equity
Shareholder equity movements include the current year loss (including discontinued operations) of $174.2m and other comprehensive income of
$0.9m for a net movement of $173.3m. Other equity movements included the share buy-back of ($10.9m) and share based payments reserve net
increase $2.6m.
Cash flow
A summary of the net operating cash flows is as follows:
2024
$M
2023
$M
Net operating cash flows before working capital movements
(0.7)
(188.1)
Working capital (investments) / releases
(14.6)
145.4
Net Operating cash flows
(15.3)
(42.7)
Less estimated cashflows relating to discontinued operations (incl transaction costs) outflows / (inflows)
23.4
(8.8)
Estimated net operating cashflows from continuing operations
8.1
(51.5)
Net operating cash for FY24 was an outflow of $15.3m. Operating cash flow was impacted by discontinued operations including payments for certain
operating expenses and payments for gross-to-net liabilities for the divested Retail Generics business. Excluding discontinued operations, operating
cashflow was an inflow of $8.1m reflective of an improved profit profile together with improved continuing NWC profile.
Operating cashflows related to discontinued operations were determined in a manner consistent with total operating cashflows in that the profit/loss
from discontinued operations was adjusted for non-cash items and working capital movements relating to the discontinued operations.
Earnout payments are deferred / variable consideration for asset acquisitions (or asset disposals in the case of the Metrics sale) and are disclosed in
investing cashflows and therefore are not included in operating cashflows. Refer investing cashflows below.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2024
5
Investing cash flows
2024
$M
2023
$M
53.4
473.5
2024
$M
2023
$M
(19.9)
(431.9)
Notable cash flows during the period included:
•
•
•
•
$8.0m payments for net capital expenditure;
$12.9m payments for intangible asset acquisitions relating to the RHOFADE® acquisition;
$89.3m received from liquidating marketable securities; and
Earn-out and deferred settlement payments totalling $21.8m.
The pcp included proceeds from the sale of Metrics Contract Services and Retail Generics.
Financing cash flows
Notable cash flows during the period included:
•
•
•
•
Net repayment of borrowings (receivables facility) of $10.9m;
Net interest receipts $5.7m;
Lease payments (right-of-use) assets $3.7m; and
On-market share buyback program payments $10.9m.
The pcp included repayment of the syndicated loan facility and payment of the special dividend using proceeds from the sale of Metrics Contract
Services.
Cash on hand plus marketable securities total $149.3m at 30 June 2024 representing a decrease of $70.9m from 30 June 2023 for the reasons outlined
above.
Reporting Segments
The Consolidated Entity operates in three operating segments being International, Women’s Health (formerly BPD) and Dermatology (formerly PPD).
During the previous period, the Consolidated Entity sold the MCS segment and the Retail Generics business and has therefore included MCS and Retail
Generics in discontinued operations (refer Note 6). The Retail Generics business was previously reported as part of the Portfolio Products Division
(PPD) segment which also included Dermatology. Following the Retail Generics sale, the segment is now Dermatology only. The segment note in the
financial statements (Note 2) shows the revenue, gross profit (GP), direct operating expenses (opex) and the direct contribution (being the GP less
direct opex) for each segment.
Dermatology
2024
$M
2023
$M
CHANGE %
Revenue
174.9
57.0
207%
Gross profit
83.9
10.7
686%
Gross profit %
48%
19%
Direct opex (including lease depreciation)
(39.6)
(31.6)
Direct contribution
44.3
(21.0)
25%
Nature of operations
The Dermatology division distributes established dermatology products in the US.
FY24 performance
The segment’s sales were $174.9m up 207% on FY23. Gross profit was $83.9m, up 686% on FY23 and direct contribution increased $65.3m compared
to the pcp of -$21.1m. The performance of the division improved as a result of new product launches, including RHOFADE®, ACCUTANE®,
SOOLANTRA®, WYNZORA®, and a full year for authorised generic ORACEA®, which launched in late FY23. LEXETTE® was removed from the business
in FY23 but returned in FY24 after establishing a new supplier. Co-pay costs across the portfolio improved on a per-unit basis in FY24 vs. FY23 with
mix shifting towards products with more favourable gross-to-net profiles.
Women’s Health
2024
$M
2023
$M
CHANGE %
Revenue
142.8
61.9
131%
Gross profit
113.5
53.9
111%
Gross profit %
79%
87%
Direct opex (including lease depreciation)
(78.2)
(81.6)
Direct contribution
35.2
(27.7)
(4%)
Nature of operations
The Women’s Health Division distributes Women’s Health branded products in the US. This Division’s products include NEXTSTELLIS®, ANNOVERA®,
IMVEXXY®, BIJUVA® and branded pre-natal vitamins.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2024
6
FY24 performance
The segment’s sales were $142.8m, up 131% on FY23, gross profit was $113.5m, up 111% on FY23 and direct contribution was $35.2m an
improvement of $62.9m on the pcp. A material component of the FY24 growth is the full year contribution from ANNOVERA®, IMVEXXY®, BIJUVA®
and branded pre-natal vitamins compared to a six-month contribution in FY23. The sales performance of NEXTSTELLIS® improved materially during
the year as a result of refreshed sales leadership and marketing strategies.
International
2024
$M
2023
$M
Revenue
70.7
64.7
9%
Gross profit
21.3
18.9
13%
CHANGE %
Gross profit %
30%
29%
Direct opex
(12.4)
(12.1)
3%
9.0
6.9
31%
Direct contribution
Nature of operations
International’s revenues and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical
products globally (ex-US) and the provision of contract development and manufacturing services to third party customers.
FY24 performance
The International reporting segment’s revenues were $70.7m, up 9% on FY23, gross profit was $21.3m, up 13% on FY23 and direct contribution
increased 31% to $9.0m. The segment’s improved performance was driven by increased demand for KAPANOL®/KADIAN® in European and Canadian
markets, coupled with strong domestic sales of oxycodone and UROREC®. NEXTSTELLIS® also achieved year on year revenue growth of 163% in the
Australian market. Additionally, the Salisbury facility demonstrated significant step change in key operational metrics to drive revenue and earnings
growth. The sale of the US Retail Generics business contributed to the increase in third party contract manufacturing volumes.
Strategy
The Company’s core strategic priorities include the following:
KEY PRIORITIES
ACTIVITIES
• Drive growth to further increase operating leverage, through sharpened focus on sales execution
and some targeted marketing efforts
• Maximise long term value of assets, via IP portfolio management and product education via Key
Opinion Leaders (KOLs)
•
Deliver profit potential of current
Women’s Health asset portfolio
•
Differentiate channel solution to
enable preferred solution for
patients, prescribers and partners
•
•
Ensure channel strategy processes are easy to use, enabling status as preferred solution
Capital efficient and accretive business development to further the Dermatology portfolio, driving
growth in revenues and margins
•
•
Drive international profit via new
revenue streams and continuation of •
modernisation
•
Leverage capacity created by operational improvements to grow and further operating leverage
Complete modernisation upgrade program to improve productivity and capabilities, with targeted
maintenance capex thereafter
Expansion of KAPANOL®/KADIAN® in ex-AU markets
Material business risks
The Board accepts that taking and managing risk is central to building shareholder value and that the Board is responsible for the Group’s risk
management strategy. Management is responsible for implementing the Board’s strategy and for developing a control infrastructure designed to
identify and mitigate risks across operations.
The Company has implemented a Risk Management Policy with a detailed, structured approach to systematically identify, rank, mitigate, and monitor
risks. This effort, led by the Compliance and Risk function, is additive to ongoing risk management responsibilities that all employees engage in as
they accomplish their daily tasks according to Company requirements. The Company maintains a risk register and material risks are regularly reported
on and discussed with management, the Audit and Risk Committee and the Board. Further details of the Company’s approach to risk identification
and management are outlined in its Corporate Governance Statement.
The following table details some of the material risks that could affect Mayne Pharma’s business and operations but are not the only risks Mayne
Pharma faces. Other risks besides those detailed below could adversely affect Mayne Pharma’s business and operations.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2024
7
RISK
Business and strategy
NATURE OF THE RISK
•
Lack of market acceptance of NEXTSTELLIS®
•
Unsuccessful growth of dermatology distribution
channel
•
Inability to meet educational and scientific
engagement needs of the healthcare community for
our full portfolio
•
Inherent competition risk to portfolio
•
Future acquisitions, licences, and investments could
negatively affect operating results, dilute equity
ownership, increase debt, or cause significant expense
•
Inability to drive accretive growth effectively
•
Healthcare policy changes and legislative reform in
the US healthcare system
Regulatory compliance
•
•
IT systems, privacy and
cybersecurity
•
•
•
Third parties
•
•
•
•
•
•
Financial condition and
capital requirements
•
•
•
•
•
•
Loss of regulatory compliance certification for
production facilities
Noncompliance with legal or regulatory requirements
Noncompliance with privacy and data security laws,
regulations, and guidance
Cyber security breach, data theft, or data leakage
Significant disruption to our technology systems
Quality or compliance failure in product
manufacturing by third party suppliers
Noncompliance of our consultants or commercial
partners with regulatory standards and requirements
Supply issues for key product
Share your feedback
Discover